AsclepiX Therapeutics, Inc. — Form D

AsclepiX Therapeutics, Inc. of Bethesda, MD, a company, filed a Form D exempt-offering notice with the SEC on 2020-06-11. The offering totals $35.0M, of which $10.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Steven S Altschuler, MDDirectorBaltimore, MD
Joshua S BarerDirectorBaltimore, MD
Jordan J GreenDirectorPorte Vedra Beach, FL
Aleksander S Popel, PhDDirectorBaltimore, MD
Kevin S Slawin, MDDirectorBaltimore, MD
Sapna S SrivastavaDirectorBaltimore, MD
Kevin S Slawin, MDExecutive OfficerBaltimore, MD
Steven AltschulerDirectorWATERTOWN, MA
Chris GarabedianDirectorSan Francisco, CA
Robert DempseyExecutive OfficerBethesda, MD
Ben AskewDirectorBethesda, MD
Josh BarerDirectorBethesda, MD
Aleksander PopelExecutive OfficerBethesda, MD
Sapna SrivastavaDirectorBethesda, MD
Amir ShojaeiExecutive OfficerBethesda, MD
Niranjan PandeyExecutive OfficerBethesda, MD
Jill TierneyExecutive OfficerBethesda, MD
Jordan GreenDirectorBethesda, MD
Jordan J GreenExecutive OfficerPorte Vedra Beach, FL
Joshua BarerDirectorRochester, MI
Aleksander S Popel, PhDExecutive OfficerBaltimore, MD
Wendy PerrowDirectorBaltimore, MD
Wendy PerrowExecutive OfficerBaltimore, MD
Aleksander Popel, PhDDirectorBaltimore, MD
Kevin Slawin, MDDirectorBaltimore, MD

Other filings by this issuer (4)

FiledFormOfferingSold
2024-04-26D$12.5M$10.0M
2019-06-17D/A$10.0M$7.7M
2018-10-25D$7.5M$3.9M
2017-02-09D$1.0M$175K

More